Prevention of Thromboembolic Events in Atrial Fibrillation

• References

• 1 Godtfredsen J. Atrial fibrillation: Course and prognosis — a follow-up study of 1212 cases. Munksgaard; Copenhagen. 1975
• 2 Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473
• 3 Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiol-ogic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982; 306: 1018-1022
• 4 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988
• 5 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147: 1561-1564
• 6 Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham Study. Neurology 1978; 973-977
• 7 Lin HL, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996; 27: 1760-1764
• 8 Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. Stroke 1996; 10: 1765-1769
• 9 Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 28: 175-179
• 10 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511
• 11 Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539
• 12 Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. for the CAFA study coinvestigators Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355
• 13 Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gomick CC. et al. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412
• 14 Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-691
• 15 EAFT (European Atrial Fibrillation) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342: 1255-1262
• 16 Petersen P, Kastrup J, Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cerebral Blood Flow 1989; 9: 422-425
• 17 Cox JL, Canavan TE, Schuessler RB. et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-426
• 18 O’Neill PG, Puleo PR, Bolli R, Rokey R. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am Heart J 1990; 120: 353-359
• 19 Chia BL, Choo MH, Yan PC, Ee BK, Lee CN, Shears JH. Intra-atrial smokelike echoes and thrombi formation. Chest 1989; 95: 744-749
• 20 Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A, Arm-strong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation. Stroke 24 1993; 1015-1019
• 21 Black IW, Hopkins AP, Lee LCL, Walsh WF. Left atrial spontaneous echo contrast: A clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18: 398-404
• 22 Totaro R, Corridoni C, Marini C, Marsili R, Prencipe M. Transcranial Doppler evaluation of cerebral blood flow in patients with paroxysmal atrial fibrillation. Ital J Neurol Sci 14 1993; 451-454
• 23 Gulløv AL, Pott F, Koefoed BG, Petersen P, Secher NH. Transcranial Doppler determined cerebral artery blood velocity during cycling in atrial fibrillation. Eur J Neurol 1995; 2 (02) 20
• 24 Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 21 1990; 47-51
• 25 Asakura H, Hifiimi S, Jokaji H, Saito M, Kumbashiri I, Uotani C, Morishita E, Yamazaki M, Shibata K, Mizuhashi K, Mifune J, Matsuda T. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagulation and Fibrinolysis 3 1992; 469-473
• 26 Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikzadeh A, Diederich KW. Detection of a hypercoagulable state in non-valvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 75 1996; 219-223
• 27 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 1994; 1449-1457
• 28 The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 116 1992; 06-12
• 29 Gulløv AL, Koefoed BG, Petersen P. Bleeding complications to longterm oral anticoagulant therapy. J Thrombos Thrombolys 1994; 1: 17-25
• 30 Hylek EM, Skatts SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335 1996; 540-545
• 31 The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333 1995; 05-10
• 32 Poller L, McKeman A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 295 1995; 1309-1312
• 33 MacCallum PK, Thompson JM, Poller L. Effect of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thromb Haemost 64 1990; 511-515
• 34 Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low dose of warfarin can prevent thrombosis in central venous catheters. Ann Int Med 112 1990; 423-428
• 35 Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. Br Med J 303 1991; 219-220
• 36 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 348 1996; 633-638
• 37 Primary preventive effects of anticoagulants and acetylsalicylic acid on arterial thromboembolism in patients with non-valvular atrial fibrillation in general practice (PATAF). Abstract Stroke 1993; 10: 1619
• 38 Koefoed BG, Gultøv AL, Petersen P. The second Copenhagen atrial fibrillation, aspirin and anticoagulant therapy (AFASAK 2). Methods and design. J Thrombos Thrombolys 2 1995; 125-130
• 39 Pengo V, Barbero F, Zasso A, Biasiolo A, Nante G, Dalla VoltaS. A trial of fixed minidose warfarin in non-rheumatic atrial fibrillation: MIWAF. In: IV International symposium: Heart-brain Interactions. Bologna; Italy: 1996. 116. (Abstract book)
• 40 Prystowsky EN, Benson W, Fuster W, Hart RG, Kay N, Myerburg RJ, Naccarelli GV, Wyse G. Management of patients with atrial fibrillation. A statement for the healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277